Meningococcal serogroup B vaccine (4CMenB): Booster dose in previously vaccinated infants and primary vaccination in toddlers and two-year-old children

Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules

“…24 One previous study in Europe found variable waning of bactericidal antibodies in the first 12 months after 2 doses of 4CMenB given at 12 and 14 months or 13 and 15 months. 25 After 12 months, 56%-75% of participants had hSBA titres of 1:5 or more against H44/76, 94%-97% against 5/99 and 6%-18% against NZ98/254. †GMR is the ratio of geometric mean titre (GMT) postvaccination to prevaccination.…”

Persistence of the immune response after 4CMenB vaccination, and the response to an additional booster dose in infants, children, adolescents, and young adults

“…In infants, antibody persistence was assessed after primary vaccination in 3-dose (2 + 1) and 4-dose (3 + 1) vaccination schedules. [21][22][23][24][25][26][27][28] In children older than 1 year of age, adolescents, and young adults, persistence was assessed after receiving two priming doses at an interval of at least 1 month. Studies/groups that assessed persistence after three-dose priming in children adolescents and young adults are not included here because the recommended schedule for these age groups is two doses.…”

“…Antibody persistence following vaccination in infancy was measured in five studies for up to 36 months after the last 4CMenB dose (Table 1). [21][22][23][24][25][26][27][28] In Study 1, infants received three doses of 4CMenB at either 2, 4, 6 months or 2, 3, 4 months of age concomitantly with routine vaccines (diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio and Haemophilus influenzae type b vaccine, and 7-valent pneumococcal conjugate vaccine), 30 and received a fourth dose of 4CMenB 6, 12, or 18 months later. Antibody persistence was assessed 24 to 36 months after the fourth dose.…”

“…22 In Study 2, infants received 4CMenB at 2, 4, and 6 months with a fourth dose administered with or without measlesmumps-rubella-varicella vaccine at 12 months of age. 23,24 One year after the fourth dose, the percentage of children with hSBA titers ≥4 was 97% for NadA, 62% for fHbp, 36% for NHBA, and 17% for PorA. 24 Two small studies (Study 3 25,26 and Study 4 27,28) assessed antibody persistence after 4-dose (3 + 1 starting at 2 months of age with booster at 12 months) and 3-dose (2 + 1 starting at 6 months of age with booster at 12 months) priming, respectively.…”

“…23,24 One year after the fourth dose, the percentage of children with hSBA titers ≥4 was 97% for NadA, 62% for fHbp, 36% for NHBA, and 17% for PorA. 24 Two small studies (Study 3 25,26 and Study 4 27,28) assessed antibody persistence after 4-dose (3 + 1 starting at 2 months of age with booster at 12 months) and 3-dose (2 + 1 starting at 6 months of age with booster at 12 months) priming, respectively. At 40 months of age, the percentage of children with hSBA titers ≥4 was 36% to 65% for fHbp, 76% to 100% for NadA, 67% to 79% for NHBA, and 14% to 41% for PorA.…”